Header Logo

Connection

MICHAEL JAMES OVERMAN to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Biomarkers, Tumor.
MICHAEL JAMES OVERMAN
Connection Strength
1.446
Biomarkers, Tumor
  1. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:207-215.
    View in: PubMed
    Score: 0.173
  2. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11; 7(41):67495-67506.
    View in: PubMed
    Score: 0.144
  3. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. 2016 06; 27(6):1068-1074.
    View in: PubMed
    Score: 0.138
  4. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. 2021 01 01; 27(1):120-130.
    View in: PubMed
    Score: 0.048
  5. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer. 2021 06; 20(2):137-147.e1.
    View in: PubMed
    Score: 0.048
  6. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
    View in: PubMed
    Score: 0.045
  7. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 03; 19(1):48-56.e2.
    View in: PubMed
    Score: 0.044
  8. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.044
  9. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010.
    View in: PubMed
    Score: 0.043
  10. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep. 2019 Jan 30; 21(2):5.
    View in: PubMed
    Score: 0.042
  11. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1409-1417.
    View in: PubMed
    Score: 0.042
  12. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res. 2019 01 15; 25(2):641-651.
    View in: PubMed
    Score: 0.042
  13. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709.
    View in: PubMed
    Score: 0.041
  14. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.039
  15. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol. 2017 Nov 01; 3(11):1546-1553.
    View in: PubMed
    Score: 0.039
  16. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. 2017 Dec; 24(13):4051-4058.
    View in: PubMed
    Score: 0.038
  17. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
    View in: PubMed
    Score: 0.038
  18. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. 2017 06; 25(6):1809-1817.
    View in: PubMed
    Score: 0.037
  19. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer. 2016 08 22; 16:668.
    View in: PubMed
    Score: 0.036
  20. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.033
  21. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res. 2015 Feb 15; 21(4):899-906.
    View in: PubMed
    Score: 0.032
  22. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.031
  23. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
    View in: PubMed
    Score: 0.022
  24. Picking the right road for metastatic colorectal cancer patients. Oncology (Williston Park). 2008 Nov 30; 22(13):1482-3.
    View in: PubMed
    Score: 0.021
  25. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024 02 05; 7(2):e240260.
    View in: PubMed
    Score: 0.015
  26. Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma. Hum Pathol. 2023 09; 139:117-125.
    View in: PubMed
    Score: 0.014
  27. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2023 05 01; 277(5):813-820.
    View in: PubMed
    Score: 0.013
  28. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.
    View in: PubMed
    Score: 0.013
  29. Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2021 07; 233(1):82-89.e1.
    View in: PubMed
    Score: 0.012
  30. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670.
    View in: PubMed
    Score: 0.012
  31. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer. 2019 Oct 17; 19(1):965.
    View in: PubMed
    Score: 0.011
  32. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer. 2019 02; 120(3):340-345.
    View in: PubMed
    Score: 0.011
  33. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
    View in: PubMed
    Score: 0.010
  34. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol. 2018 08; 14(18):1869-1874.
    View in: PubMed
    Score: 0.010
  35. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.010
  36. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.
    View in: PubMed
    Score: 0.010
  37. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017 04 01; 28(4):741-747.
    View in: PubMed
    Score: 0.009
  38. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol. 2017 Jan; 24(1):187-193.
    View in: PubMed
    Score: 0.009
  39. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21.
    View in: PubMed
    Score: 0.008
  40. Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol. 2014 May; 45(5):1015-23.
    View in: PubMed
    Score: 0.007
  41. High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol. 2013 Aug; 37(8):1192-200.
    View in: PubMed
    Score: 0.007
  42. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.